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Abstract Human platelets express several sarco/endoplasmic
reticulum Ca2+ATPase (SERCA) isoenzymes: SERCA2b of 100
kDa apparent molecular mass and two distinct enzymes of 97
kDa, one of them identified as being the SERCA3a isoform. The
molecular identity of the third enzyme specifically recognized by
the PL/IM430 monoclonal antibody has remained elusive. First,
the study of the 3P-end part of platelet SERCA3 mRNA, by
means of RT-PCR amplification using sets of primers covering
the N33 to N (ultimate) exons of the human SERCA3 sequence,
revealed the presence of two distinct mRNA sequences,
SERCA3a and a longer variant. Second, this additional sequence
was identified as SERCA3b and found to refer to the insertion of
a new exon of 73 bp, located at bp 349 from the beginning of the
intronic sequence, linking the penultimate (N31) exon to the last
exon (N) of the human SERCA3 gene. Third, a relationship
between the expression of this SERCA3b mRNA and the PL/
IM430 recognizable SERCA protein was observed. SERCA3b
mRNA was found to be absent in epithelial HeLa cells not
recognized by the PL/IM430 antibody and the expression of this
SERCA3b RNA species correlated with that of the SERCA
protein recognized by PL/IM430 which was down-modulated in
the platelet precursor megakaryocytic CHRF 288-11 cell line as
well as upon in vitro lymphocyte activation. Taken together,
these results strongly support the notion of the presence of the
SERCA3b protein in human cells by showing SERCA3b mRNA
in platelets and the fact that the protein corresponding to this
mRNA species is very likely the 97 kDa protein recognized by
the PL/IM430 antibody.
z 1998 Federation of European Biochemical Societies.
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1. Introduction
Ca2 ions integrate key events of cell function as a dynamic
Ca2 signal which appears in a spatio-temporal manner as
Ca2 waves or spikes. Numerous and distinct processes are
involved in this Ca2 signalling, including the release of Ca2
from intracellular Ca2 stores. It is now increasingly thought
that there are at least two types of intracellular Ca2 pools:
inositol 1,4,5 trisphosphate (IP3)-sensitive Ca2 pools and
IP3-insensitive Ca2 pools [1,2]. This multiplicity of Ca2
pools may suggest a functional speci¢city in terms of the
control of their Ca2 content, which depends upon the activ-
ities of sarco/endoplasmic reticulum Ca2-transport ATPases
(SERCAs). In recent years, evidence has emerged of a diver-
sity of SERCA isoforms which may sustain di¡erent Ca2
pools. Indeed, SERCAs are encoded by three distinct genes,
termed SERCA1 to 3 which, upon alternative splicing, give
rise to various mRNAs and protein isoforms. SERCA1 gives
the SERCA1a and SERCA1b isoforms, expressed in fast skel-
etal muscle [3]. The SERCA2 gene gives rise to the SERCA2a
isoform expressed in cardiac muscle and to the ubiquitous
SERCA2b isoform found in smooth muscle cells and non-
muscle cells [4]. Much less is known concerning SERCA3. A
SERCA3a cDNA was cloned from rat kidney [5], mRNA was
found to be expressed in various non-muscle cells [5^9] and
the corresponding SERCA3a protein was identi¢ed in plate-
lets and other non-muscle cells [7,10]. Finally, part of the 3P-
end of the human SERCA3 gene, as well as alternative splic-
ing of the SERCA3 primary transcript have been described
[11] concomitantly with two (SERCA3a and SERCA3b)
mouse cDNAs [12,13]. However, the evidence for a SERCA3b
protein remains undescribed.
Intriguingly, using controlled trypsinolysis of human plate-
let membrane vesicles followed by immunostaining of the re-
sulting fragments by the monoclonal antibody PL/IM430, Ko-
vaØcs et al. [14] described a SERCA protein previously
unknown in the SERCA family, the so-called PL/IM430 rec-
ognizable 97 kDa SERCA. In particular, this SERCA protein
was clearly shown to be distinct from the SERCA3a protein
by the absence of recognition by the PL/IM430 antibody of
the transfected human protein [11]. Moreover, these two SER-
CA3a and PL/IM430 recognizable 97 kDa SERCA isoforms,
which were co-expressed in platelets, had distinct intracellular
localizations [15] and were di¡erentially expressed in JUR E6-
1 and HeLa cell lines [16].
The aim of the present work was to elucidate the molecular
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nature of the PL/IM430 recognizable 97 kDa SERCA isoform
based on the hypothesis that this protein may be identical to
the SERCA3b protein. The results show the presence of two
SERCA3 mRNA species (SERCA3a and SERCA3b) in
platelets and demonstrate that the SERCA3b species refers
to the presence of a new exon of 73 bp located in the intronic
sequence preceding the last exon N of the SERCA3 gene.
Moreover, a relationship is found between the expression of
the SERCA3b mRNA and that of the PL/IM430 recognizable
97 kDa SERCA using di¡erent models of expression and
regulation of the expression of this protein.
2. Materials and methods
2.1. Cell culture and treatments
The JUR E6-1 (T lymphoblastoid) and HeLa (epithelial) cells were
from American Type Culture Collection. The CHRF 288-11 (mega-
karyocytic) cell line was provided by Dr. M. Lieberman, Cincinnatti,
OH, USA. Cells were grown in RPMI 1640 medium (GIBO BRL,
Paisley, Scotland) supplemented with 10% heat-inactivated fetal calf
serum, 50 units/ml penicillin, 0.05 mg/ml streptomycin and 2 mM L-
glutamine (Boehringer, Mannheim, Germany). HeLa cells were grown
in Eagle’s minimal essential medium (GIBCO BRL, Paisley, Scotland)
with non-essential amino acids and Earle’s balanced salt solution. All
cell lines were grown at 37‡C with 5% CO2 in a humidi¢ed atmos-
phere. Exponentially growing JUR E6-1 cells were treated by PMA
plus ionomycin as described [17].
2.2. Membrane preparation
Cell line membranes were prepared as in [18]. Human platelet mem-
branes were prepared by a similar method, as described previously
[14]. The protein concentration of the di¡erent membrane prepara-
tions was determined by the Bradford method [19] using Q-globulins as
standard.
2.3. SDS-PAGE
Proteins were submitted to 7.5% SDS-polyacrylamide gel electro-
phoresis (SDS-PAGE) [20] and electrotransferred onto nitrocellulose
membranes (Schleicher p Schuell, Dassel, Germany).
2.4. Antibody preparation and characterization
The monoclonal antibody PL/IM430 [21,22] was puri¢ed from cul-
ture supernatant of the corresponding hybridoma cell line [14]. This
antibody speci¢cally recognized one of the 97 kDa SERCA isoforms
in platelets and in di¡erent human cell lines [23,24].
2.5. Western blotting
Nitrocellulose membranes were treated for Western blotting using
1 Wg/ml of the monoclonal antibody PL/IM430 [14] and incubated
with a 1:1000 dilution of the anti-mouse IgG horseradish-peroxidase
conjugate (Jackson Immunoresearch, West Grove, PA, USA). Anti-
body binding was detected using ECL (enhanced chemiluminescence)
Western blotting reagents (Amersham International, Life Science, Lit-
tle Chalfont, UK).
2.6. Isolation of total RNA
For platelet RNA, the isolation of platelets was slightly modi¢ed by
blood dilution in isotonic saline solution prior to centrifugation steps
to isolate platelet-rich plasma (PRP). PRP was withdrawn to within
1 ml of the bu¡y-coat in order to avoid leukocyte contamination.
Under these conditions, the contamination of platelets by other blood
cells was less than 1 leukocyte in 4000 platelets. Total RNA was
isolated from platelets and cell lines [25], using the RNA Plus solution
(Bioprobe, Montreuil sous Bois, France).
2.7. Reverse transcription-PCR analysis
500 ng of total RNA was used as template for ¢rst strand-speci¢c
cDNA synthesis in a 10 Wl reaction mixture containing PCR bu¡er (10
mM Tris-HCl pH 8.3, 50 mM KCl), 5 mM MgCl2, 2.5 WM of oligo
d(T)16, 1 mM of each dNTP, 10 U of RNAse inhibitor and 25 U of
MuLV reverse transcriptase (Perkin Elmer, Branchburg, NJ, USA).
The reaction mixture was incubated for 30 min at 42‡C, then heated
for 5 min at 99‡C. RT reaction was used as template for PCR in a 50
Wl reaction mixture including PCR bu¡er, 2 mM MgCl2, 0.15 WM of
the forward and reverse primers (Eurogentec, Leuven, Belgium) and
1.25 U of AmpliTaq DNA polymerase (Thermus aquaticus) (Perkin
Elmer, Branchburg, NJ, USA). PCR was conducted for 30 s at
94‡C, 2 min at 55‡C and 2 min at 72‡C for 30 or 50 cycles. Ampli-
¢cations were followed by an extension step for 7 min at 72‡C. Am-
pli¢cation products were electrophoresed on 1.5% (w/v) agarose gels
stained by ethidium bromide. For Southern blotting [26], the ampli-
¢cation products were blotted onto nylon membranes (Hybond N+
from Amersham International). Prehybridization and hybridization
using 5 ng/ml of labeled oligo or DNA probe (3P-oligo or direct
nucleic acid labeling kits, Amersham) were performed at 42‡C. Mem-
branes were washed and detection was performed using the ECL
detection system and Hyper¢lms ECL (Amersham).
The SERCA2b-speci¢c cDNA probe was cloned by screening a
human platelet cDNA library [27]. The SERCA3-speci¢c probes
used were either SERCA3 fragments which had been ampli¢ed by
PCR and corresponded to nucleotides 2674 to 3000, or 3P-oligolabeled
n-1 and ct SERCA3 primers located in positions 2956^2976 and 2981^
3000 of the sequence published by Dode et al. [11] respectively.
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Fig. 1. Evidence for two SERCA3 mRNA species in human plate-
lets. A: Study of the 3P-end part of the SERCA3 mRNA. A sche-
matic representation of the 3P-end of the human SERCA3 gene and
SERCA3 mRNA [11] is shown in the upper part of the ¢gure.
Boxes represent exons while lines represent introns. The larger and
smaller rectangles correspond respectively to the coding and non-
coding sequences. This SERCA3 mRNA was studied by RT-PCR
(middle part) using di¡erent primers located either in the N33 exon
n-3, or in the N31 exon n-1, or in the ultimate exon: ct (C-terminal
region of the deduced SERCA3 protein) or nc (non-coding region
of SERCA3). The predicted sizes of the ampli¢cation products and
the SERCA3 probe are indicated in the lower part of the ¢gure. B:
SERCA3 mRNA ampli¢cation in human platelets. 500 ng of total
RNA isolated from human platelets was submitted to RT-PCR for
50 cycles using the forward n-3 primers and either the n-1 reverse
primers (lane 1), the ct reverse primers (lane 2) or the nc reverse
primers (lane 3). Ampli¢cation products were analyzed by Southern
blotting using the SERCA3 probe indicated above. Numbers indi-
cate the sizes of the ampli¢cation products. The ¢gure is representa-
tive of four independent experiments.
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3. Results
3.1. Evidence for two SERCA3 mRNA species in human
platelets
Since alternative splicing may be a general feature in the
SERCA family, we looked for di¡erences in the 3P-end of the
human SERCA3 mRNA. We used RT-PCR to amplify SER-
CA3 mRNA and designed di¡erent sets of primers allowing
the 3P-end region to be covered between the N33 and N
exons, according to the published nomenclature [11] of the
human SERCA3 gene (Fig. 1A). The forward n-3 primers
5P-GAGTCACGCTTCCCCACCACC-3P corresponded to nu-
cleotides 2674^2694 and the reverse primers n-1 5P-CA-
TGTGGTTCCGGGACAGGTA-3P, ct 5P-TCACTTCTGGC-
TCATTTCTT-3P and nc 5P-GCCTGTCATTTATCCGGCG-
3P corresponded to the inverse sequences of the nucleotide
stretches 2956^2976, 2981^3000 and 3113^3131 respectively.
The corresponding sizes of the previously known SERCA3a
ampli¢cation products were 303, 327 and 458 bp. Fig. 1B
shows the analysis of the ampli¢cation products obtained.
Control ampli¢cations in the absence of RT (not shown)
did not result in detectable ampli¢cation products, in agree-
ment with the absence of DNA contamination in RNA prep-
arations. Two di¡erent RNAs were obtained depending upon
the sets of primers used (compare lane 1 to lanes 2 and 3).
While unique SERCA3 ampli¢cation products were obtained
with primers covering the region between the N33 and the
N31 (penultimate) exons (lane 1), additional products of 400
and 531 bp were detected when using primers covering the
region between the N33 and the N (ultimate) exons (lanes 2
and 3), thus presenting an apparent additional sequence of
about 70 bp.
This could suggest the presence of two SERCA3 species,
SERCA3a and SERCA3b, in platelets and that the latter
may include a still unidenti¢ed new exon in the intronic se-
quence linking the penultimate and the ultimate exons.
3.2. Identi¢cation of the human SERCA3b mRNA in platelets
To locate this potential exon, we took advantage of the
recently published mouse SERCA3a and SERCA3b cDNAs.
Both cDNAs were identical between nt 1 and 2980, but di-
verged downstream of this site. An additional sequence of
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Fig. 3. Cell-dependent expression of the PL/IM430 recognizable 97
kDa SERCA and of the human SERCA3b mRNA. A: Compara-
tive SERCA3 mRNA expression in human platelets and HeLa cells.
500 ng of total RNA was isolated from human platelets (lane 1)
and HeLa (lane 2) cells and submitted to RT-PCR for 50 cycles us-
ing SERCA2b and SERCA3 n-3 forward and nc reverse primers.
The ampli¢cation products were analyzed by Southern blotting as
in Figs. 1 and 2. Numbers indicate the sizes of SERCA2b (upper
part) and SERCA3a and SERCA3b (lower part) ampli¢cation prod-
ucts. This ¢gure is representative of three independent experiments.
B: Study of SERCA3b mRNA expression in human platelets, JUR
E6-1 and HeLa cells. 500 ng of total RNA was isolated from hu-
man platelets (lanes 1 and 4), JUR E6-1 (lanes 2 and 5) and HeLa
(lanes 3 and 6) cells and was submitted to RT-PCR for 50 cycles
using SERCA2b and SERCA3 n-3 forward and r3b reverse primers.
Ampli¢cation products were analyzed on ethidium bromide stained
gels (lanes 1 to 3) and by Southern blottings (lanes 4 to 6), using
the SERCA2b (upper parts) and 3P-oligolabeled n-1 SERCA3
probes (lower parts). Numbers indicate the sizes of the ampli¢cation
products. This ¢gure is representative of four independent experi-
ments.
Fig. 2. Evidence for SERCA3b mRNA in human platelets. A: Sche-
matic representation of the human SERCA3 gene and SERCA3b
mRNA. The location of the speci¢c SERCA3b exon (see Section 3)
and the deduced SERCA3b mRNA are represented in the upper
part of the ¢gure. Boxes represent exons while lines represent in-
trons. The larger and smaller rectangles correspond respectively to
the coding and non-coding sequences. The forward f3b and reverse
r3b SERCA3b-speci¢c primers designed to amplify SERCA3b
mRNA, the predicted sizes of the SERCA3b ampli¢cation products
and the n-1 and ct SERCA3 probes are indicated in the lower part
of the ¢gure. B: Speci¢c SERCA3b mRNA ampli¢cation. 500 ng of
total RNA isolated from human platelets was submitted to RT-
PCR for 30 cycles using SERCA2b primers (lane 1), n-3 forward
and r3b reverse primers (lane 2), or f3b forward and nc reverse pri-
mers (lane 3). Ampli¢cation products were analyzed on ethidium
bromide stained gels (upper part) and by Southern blotting (lower
part) using the SERCA2b probe (lane 1), 3P-oligolabeled n-1 (lane
2) and ct (lane 3) SERCA3 probes. Numbers indicate the sizes of
the ampli¢cation products. The ¢gure is representative of four inde-
pendent experiments. C: SERCA3 amino acid similarity compari-
son. The C-terminal part of the human SERCA3b and SERCA3a
amino acid sequences are represented in the lower lines and aligned
with the corresponding parts of the mouse SERCA3b and SER-
CA3a sequences [12,13] represented in the upper lines. Identical ami-
no acids are connected by vertical lines. The numbers on the left in-
dicate the splicing locations and the numbers on the right indicate
the ends of the amino acid sequences.
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73 bp was observed in SERCA3b cDNA, modifying the read-
ing frame and leading to the substitution of the last 6 amino
acids of SERCA3a isoform by 45 amino acids in SERCA3b
isoform. We searched for a corresponding 73 bp exon in the
last intron of human SERCA3 gene. Such a 73 bp exon,
presenting canonical exon/intron boundary sites, was found
at 349 bp from the beginning of the last human intronic se-
quence (Fig. 2A), and presented 78% similarity with the
mouse SERCA3b exon. Based on the di¡erences of approx.
70 bp observed between the two SERCA3 RNA species in
platelets, we thus looked for SERCA3b RNA, by selecting
speci¢c human primers to amplify this RNA species. The
forward primers n-3 and f3b 5P-CCTTCTCAGGA-
CAGTCTCG-3P corresponding to nucleotides 2982^3001,
the reverse primers r3b 5P-TGCGAGACTGTCCTGA-
GAAGG-3P corresponding to the reverse sequence of the nu-
cleotide stretch 2982^3003 and the nc primers were used to
amplify both upstream and downstream regions £anking this
exon. The corresponding sizes of the SERCA3b ampli¢cation
products were 328 and 223 bp. Fig. 2B shows the results of
these ampli¢cations performed with platelet RNA together
with those of SERCA2b (270 bp), used as an internal control
(lane 1). As shown either on agarose gels stained by ethidium
bromide (upper part of the ¢gure), or by Southern blotting
(lower part of the ¢gure), both the expected SERCA3b am-
pli¢ed products were detected (see lanes 2 and 3), thus con-
¢rming the presence of this exonic sequence in SERCA3b
mRNA. This was further demonstrated by sequencing the
223 bp ampli¢ed products which showed 100% identity with
the putative human exon (data not shown). Hence, this al-
lowed us to deduce the human SERCA3b amino acid se-
quence in part C of Fig. 2 which revealed a similarity of
63% with the mouse amino acid sequence.
3.3. Relationship between the SERCA3b mRNA and the
PL/IM430 recognizable 97 kDa SERCA protein
3.3.1. Correlation between the PL/IM430 recognizable 97
kDa SERCA and SERCA3b mRNA expression in di¡erent
cell lines. We ¢rst took advantage of our previous work
which showed a di¡erential expression of the SERCA3a and
PL/IM430 recognizable 97 kDa SERCA proteins in di¡erent
cell lines, and in particular, we focussed on the absence of the
latter protein in HeLa cells [16]. RNA was isolated from these
cells and tested for expression of both SERCA3 mRNA spe-
cies (lower parts of Fig. 3) as in Fig. 1 as well as that of
SERCA2b mRNA as internal controls (upper parts of Fig.
3). Fig. 3A shows the results of this SERCA3 study in HeLa
cells (lane 2) compared with platelets (lane 1), which revealed
the presence of SERCA3a RNA in these epithelial-like cells,
as demonstrated by the presence of the related 458 bp ampli-
¢ed products (compare lanes 1 and 2), but the absence of the
additional SERCA3b RNA species (lane 2). This result was
further con¢rmed (Fig. 3B) by studying the speci¢c expression
of SERCA3b in platelets (lanes 1 and 4) and HeLa cells (lanes
3 and 6), as well as in another hemopoietic cell line, the
lymphoblastoid JUR E6-1 (lanes 2 and 5) previously shown
to express the PL/IM430 recognizable SERCA [24]. SER-
CA3b was detected in the two hemopoietic cells (JUR E6-1
and platelets) when analyzed either on agarose gels stained by
ethidium bromide (lanes 1 to 3) or by Southern blotting (lanes
4 to 6), but no expression of SERCA3b was found in HeLa
cells.
3.3.2. Correlation between the expression of the PL/IM430
recognizable 97 kDa SERCA and SERCA3b mRNA in the
megakaryocytic lineage. Second, we compared the expres-
sions of the PL/IM430 recognizable 97 kDa SERCA and
SERCA3b mRNA in the megakaryocytic lineage by studying
the cell line CHRF 288-11 described as representative of plate-
let precursor [28] (Fig. 4). CHRF 288-11 cells were cultured
and either treated for membrane protein preparation or for
total RNA isolation. Proteins were electrophoresed and im-
munoblotted using the PL/IM430 antibody (part A). RNA
was submitted to RT-PCR as above (part B) using SERCA2b
FEBS 19873 20-2-98
Fig. 5. Comparative regulation of the expression of the PL/IM430
recognizable 97 kDa SERCA and of the human SERCA3b mRNA.
JUR E6-1 cells were treated for 4 days with either DMSO as vehicle
(lanes 1) or 10 nM PMA and 0.5 mM ionomycin (lanes 2). They
were then either treated for whole cell lysate or for total RNA iso-
lations. 25 Wg of cell lysate proteins were electrophoresed and im-
munoblotted using the PL/IM430 antibody (part A). 500 ng of total
RNA was submitted to RT-PCR (part B) for 30 cycles using SER-
CA2b primers (upper part), f3b forward and nc reverse primers
(lower part). The ampli¢cation products were analyzed by Southern
blotting using the SERCA2b (upper part) and the 3P-oligolabeled ct
SERCA3 probe (lower part). Numbers indicate the molecular mass
of the PL/IM430 recognizable 97 kDa SERCA (part A) or the size
of SERCA3b ampli¢cation products (part B). This ¢gure is repre-
sentative of four independent experiments.
Fig. 4. Comparative expression of the PL/IM430 recognizable 97
kDa SERCA and of the human SERCA3b mRNA in the megakar-
yocytic lineage. Human platelets (lanes 1) and CHRF 288-11 (lanes
2) cells were either treated for membrane protein preparation or for
total RNA isolation. Membrane proteins (50 Wg) were electropho-
resed and immunoblotted using the PL/IM430 monoclonal antibody
(part A). 500 ng of total RNA was submitted to RT-PCR for 30
cycles (part B) using SERCA2b primers (upper part), n-3 forward
and either nc (middle part) or r3b reverse primers (lower part) and
the ampli¢cation products were analyzed by Southern blotting using
the SERCA2b (upper part) and the 3P-oligolabeled n-1 SERCA3
probe (middle and lower parts). Numbers indicate the molecular
mass of the PL/IM430 recognizable 97 kDa SERCA (part A) or the
size of the ampli¢cation products (part B). This ¢gure is representa-
tive of three independent experiments.
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primers for internal controls (upper part) and SERCA3 pri-
mers either to coamplify SERCA3a and SERCA3b (middle
part) or to amplify SERCA3b (lower part). The comparative
analysis of platelets (lanes 1) and CHRF 288-11 cells (lanes 2)
showed a parallel decrease in the expression of PL/IM430
recognizable 97 kDa SERCA (A) and of SERCA3b RNAs
(B) as revealed by both the related 531 bp products (middle
part) and the speci¢c 328 bp products (lower part).
3.3.3. Correlation between the regulation of the expression of
the PL/IM430 recognizable 97 kDa SERCA and SERCA3b
mRNA during in vitro lymphocyte activation. Finally, we
studied the regulation of the expression of SERCA3b
mRNA in JUR E6-1 cells previously shown to exhibit a
down-regulation of the PL/IM430 recognizable 97 kDa SER-
CA upon activation induced by ionomycin plus PMA [17].
Thus, we looked for comparative expression of SERCA3b
mRNA in this model (Fig. 5). JUR E6-1 cells were treated
as in [17]. Lysates were electrophoresed and immunoblotted
using the PL/IM430 antibody (part A) and RNAs were sub-
mitted to RT-PCR (part B) using SERCA2b primers for in-
ternal controls (upper part) or speci¢c SERCA3b f3b and nc
primers (lower part). Comparison of untreated (lanes 1) and
treated JUR E6-1 cells (lanes 2) showed a similar down-reg-
ulation of the expression of the PL/IM430 recognizable 97
kDa SERCA (part A) and of SERCA3b mRNA (lower part
B).
4. Discussion
This study suggests evidence for the SERCA3b protein in
human cells by showing SERCA3b mRNA in platelets and
that this mRNA species very likely encodes the still unidenti-
¢ed PL/IM430 recognizable 97 kDa SERCA protein.
First, RT-PCR of total platelet RNA demonstrated the
presence of the previously known SERCA3a species and of
a SERCA3 species about 70 bp larger. This latter mRNA
species was further identi¢ed as SERCA3b and found to arise
from the insertion of a cryptic new exon of 73 bp beginning at
position 2981 of the human SERCA3a cDNA. The insertion
of this exon modi¢es the reading frame and results in the
suppression of the stop codon used in SERCA3a. This gives
rise to SERCA3b which uses an alternative stop codon lo-
cated at bp 3044 in the non-coding part of the ultimate
exon [11]. This resulted in the deduced human SERCA3b
protein which di¡ers from SERCA3a in its C-terminal extrem-
ity, by the replacement of the last C-terminal amino acids in
SERCA3a by 45 amino acids in SERCA3b.
Hence, like SERCA1 and SERCA2 gene products, the
SERCA3 gene gives rise to two SERCA3a and 3b isoforms,
which result from an alternative splicing process [29^35,11].
Moreover, in a further similarity with SERCA2 proteins,
which present two conformational states, thus to the variable
carboxy-terminal extremities [36], the structural di¡erences in
the two SERCA3 isoforms imply modi¢cations in the three-
dimensional membrane organization of the proteins, as re-
vealed by their distinct accessibility to trypsin [14].
Second, by using di¡erent experimental models previously
tested for their expression of the PL/IM430 recognizable 97
kDa SERCA protein, a relationship was found between the
expression of this protein and that of SERCA3b mRNA: (i)
in the HeLa cell line no SERCA3b could be detected either by
RT-PCR or by using the PL/IM430 antibody; (ii) in the
megakaryocytic CHRF 288-11 cell line and platelets, the
relative expression of SERCA3b measured by RT-PCR was
correlated with SERCA protein levels measured using the PL/
IM430 antibody; (iii) in JUR E6-1 cells treated for a down-
regulation of the PL/IM430 recognizable 97 kDa SERCA [17],
a similar decrease in the SERCA3b mRNA expression was
observed. Hence, the most likely interpretation of these ¢nd-
ings is that the SERCA3b protein corresponds to the protein
recognized by the PL/IM430 monoclonal antibody.
This SERCA3 nature of the PL/IM430 recognizable 97 kDa
SERCA protein is consistent with recent data suggesting a
similarity of the PL/IM430 recognizable 97 kDa SERCA
with the SERCA3a protein. This is based on the recognition
of the protein puri¢ed by immunoa⁄nity using the PL/IM430
monoclonal antibody by the anti-SERCA3 N89 antibody,
raised against the N-terminal peptide common to both SER-
CA3 proteins (KovaØcs et al., manuscript in preparation and
[37,38]). Moreover, the SERCA3b identity of the PL/IM430
recognizable 97 kDa SERCA3 protein also explains its dis-
crimination from the SERCA3a protein. This is based on the
absence of recognition by the PL/IM430 antibody of: (i) the
two SERCA3a tryptic fragments of 80 and 25 kDa [14]; (ii)
the transfected human SERCA3a protein [11]; and (iii) the
N89 recognized SERCA3a protein expressed in epithelial
HeLa [16] or endothelial cells [39]. Consequently, one can
suggest that the PL/IM430 antibody speci¢cally recognizes
the C-terminal extremity of the human SERCA3b protein.
So, while the N89 antibody can be used to study both SER-
CA3 proteins in di¡erent species, the PL/IM430 antibody
should be useful for speci¢c study of the human SERCA3b
isoform.
To conclude, this identi¢cation of the third platelet SERCA
isoform as the SERCA3b isoform establishes the concept of
the presence of a multi-SERCA system [40] in cells such as
platelets. This observation sheds new light on the complexity
of intracellular Ca2 sequestration of non-muscle cells and
opens new avenues in the investigation of the SERCA-asso-
ciated Ca2 pools organisation and of their functional role in
cell Ca2 homeostasis and signalling.
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